Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer (GEMDOCE)
A Phase II Trial for the Use of Intravesical Gemcitabine and Docetaxel (GEMDOCE) in the Treatment of BCG naïve Non-muscle Invasive Urothelial Carcinoma of the Bladder
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Listed as NCT04386746, this PHASE2 trial focuses on Bladder Cancer and Urothelial Carcinoma Bladder and remains ongoing. Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, it has been updated 12 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Oct 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2020 — Sep 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
For direct contact, visit the study record on ClinicalTrials.gov .